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Abstract: Theranostics is a concept that integrated imaging and therapy. As an emerging ﬁeld, it embraces
multiple techniques to arrive at an individualized treatment purpose. Indocyanine green (ICG) is a near infrared
dye that has been approved by Food and Drug Administration (FDA) in USA for the use in indicator-dilution
studies in humans. ICG nanoparticles (NPs) have attracted much attention for its potential applications in
cancer theranostics. This review focuses on the preparation, application of ICG NPs for in vivo imaging (ﬂu-
orescent imaging and photoacoustic imaging) and therapeutics (photothermal therapy, photodynamic therapy
and photoacoustic therapy), and future directions based on recent developments in these areas. It is hoped
that this review might provide new impetus to understand ICG NPs for cancer theranostics.
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Introduction
Theranostic is coined originally as a term to describe
a treatment platform that combines diagnostics with
therapeutics [1]. It embraces multiple techniques to
toward the goal of personalized medicine for the ben-
eﬁt of patients. At present, a variety of nanoparti-
cles (NPs) have been developed to diagnose and treat
cancer. However, tumor heterogeneity and adaptive
resistance remain formidable challenges to diagnosis
and therapy [2]. Recently, there is an eﬀort to tan-
gle the emerging approach with nanotechnologies, in
an attempt to develop theranostic NPs. As a next-
generation nanocarrier system, theranostic NPs can
not only provide patients with various treatment op-
tions, but also can monitor therapeutic eﬃcacy follow-
ing treatments. Therefore, it can expedite clinician’s in-
dividualized therapeutic decisions [3]. At present, sev-
eral NPs including quantum dots, magnetic NPs, car-
bon nanotubes, gold nanostructures, polymeric NPs,
and silica NPs have been used as theranostic agents for
cancer diagnosis and therapy [4]. However, little num-
ber of NPs has been approved by the Food and Drug
Administration (FDA) in USA for clinical use as trans-
port vehicles, and few theranostic NPs have entered
human use.
Indocyanine green (ICG, molecular weight: 774.96
g/mol, CAS number: 3599-32-4) is an amphiphilic tri-
carbocyanine dye (Fig. 1) [5]. In 1958, ICG was ap-
proved by FDA for the use in indicator-dilution studies
in humans, and it is also one of the least toxic agents
ever administered to humans, with the only known ad-
verse reaction being rare anaphylaxis. ICG exhibits
emission maxima around 800 nm that make it highly
suitable for bio-imaging applications with high signal-
to-background ratio (Fig. 1). It also can convert the
absorbed light energy to produce heat and toxic chem-
ical species (such as singlet oxygen, superoxide anions,
and hydroxyl radicals), forming the respective bases for
photoacoustic imaging (PA), photothermal (PT) and
photodynamic (PD) therapies, respectively (Fig. 2) [5-
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Fig. 1 The chemical structure, UV-Vis and ﬂuorescent

















Fig. 2 The schematic diagram of ICG NPs for diﬀerent
applications.
8]. Therefore, ICG has been considered as a good thera-
nostic agent. However, the use of ICG for imaging ther-
apeutic applications is limited by its several drawbacks
[9]. It is mainly manifested in the following aspects: 1)
Photo-degradation: Degradation of ICG in aqueous so-
lution followed ﬁrst-order kinetics, and was accelerated
by light exposure. 2) Thermal-degradation: Higher
temperatures markedly accelerate the degradation of
ICG in aqueous solutions. 3) Aqueous-instability: ICG
undergoes degradation in aqueous media resulting in
a simultaneous loss of absorption and ﬂuorescence. 4)
Short circulation time (half-life 2-4 min). 5) Easy to
bind nonspeciﬁcally to human serum albumin and re-
sult in its rapid clearance by the liver. 6) Low ﬂu-
orescence quantum yield due to internal conversion
and photobleaching. Therefore, to overcome these lim-
itations, ICG molecular can be loaded, doped and
conjugated with diﬀerent NPs with diﬀerent prepar-
ing strategies (Fig. 3) [10]. The prepared ICG NPs
have high photostability, thermal stability, long circu-
lation time, and tumor-targeting ability [11], respec-
tively.
In this article, we will review the various types of ICG
NPs, and discuss their applications in cancer theranos-
tics. A large number of review articles describe clinical
diagnostic or therapeutic systems of ICG for the treat-
ment of cancer, however, few articles have focused on
ICG NPs capable of simultaneously imaging and treat-
ing cancer [12]. Thus, this review will focus on ICG NP
that integrate tumor imaging and therapy into a single
system. In detail, we will discuss theranostic applica-
tions of diverse ICG NPs categorized by diﬀerent car-
riers such as silica, calcium phosphate, nanoGUMBOS,
gold, PLGA, phospholipid-polyethylene glycol, PLGA-
lipid NPs, and so on (Table 1), or by diﬀerent prepar-
ing strategies (Fig. 3). These applications include: 1)
in vivo diagnostics of tumor; 2) photothermal therapy
of tumor; 3) theranostics for monitoring biological re-
sponses and therapeutic eﬃcacy following treatment.
Finally, we will address the limitations and future chal-
lenges of ICG NPs.
Table 1 Theranostic applications of diverse ICG NPs categorized by diﬀerent carriers.
NPs Imaging modalities Therapeutics Ref.
Inorganic NPs
Silica NPs NIRF, MRI PTF 28
Calcium Phosphate NPs NIRF PTT 30
Nanoparticle-assembled capsules NIRF PTT 25
NanoGUMBOS NIRF PTT 20
Organic NPs
PLGA NPs NIRF PTT 21
Pluronic F-127 NIRF PTT 18
Phospholipid-polyethylene glycol NIRF PTT 22
PLGA-lipid NIRF/PA PTT/PA/Chemotherapy 23
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Fig. 3 Commonly used techniques to prepare ICG NPs.
ICG loaded NPs
As an amphiphilic dye, ICG can be loaded into sev-
eral materials including calcium phosphosilicate [13],
poly(allylamine hydrochloride) assembled mesocapsules
[14], PLGA [15], PLGA-PEG [16], PL-PEG [17],
Pluronic F-127 [18], SiO2 [19], ionic liquids [20], and so
on. Among them, biodegradable-biocompatible, FDA
approved PLGA carriers are one of the most common
systems employed to improve ICG for theranostic appli-
cations [21]. ICG-PLAG NPs allowed passive targeting
from the blood stream into the tumor site. In addition,
after functionalized modiﬁcation, targeting ligands can
be conjugated to ICG-PLGA NPs to make them can-
cer speciﬁc. A good example is the PLGA-lipid NPs,
reported by Zheng et al. in 2012. Using the single-step
self-assemble and nanoprecipitation method, ICG can
be loaded into the biodegradable PLGA-lipid micelles
[22]. The average hydrodynamic diameter of the NPs is
102.4 ± 4 nm, which was quite stable without the size
change for several weeks. Moreover, the ICG-PLGA-
lipid NPs exhibit good biocompatibility, monodisper-
sity, signiﬁcant stability against photobleaching and
long circulation time. The targeting modality, folic
acid (FA) ligand, can be functionalized onto the micelle
surface to target the folate receptor found on tumors.
On the basis of the results, the PLGA-lecithin-PEG
NPs containing DOX and ICG were synthesized using
a single-step sonication method, reported by Zheng et
al. in 2013 [23]. The prepared theranostic nanoagents
could simultaneously deliver DOX and ICG to tumor
regions for combined chemo-photothermal therapy, and
showed higher temperature response, faster DOX re-
lease under laser irradiation, and longer retention time
in tumor. The combined treatment of ICG NPs with
laser irradiation synergistically induced the apoptosis
and death of MCF-7 and MCF-7/multidrug resistance
cell, and suppressed tumor growth in vivo. Notably,
no tumor recurrence was observed after only a single
dose of NPs with laser irradiation. Hence, the well-
deﬁned theranostic ICG NPs exhibited great potential
in targeting cancer imaging and chemo-photothermal
therapy. Similarly, Zhong et al. reported phospholipid-
polyethylene glycol (PL-PEG) NPs consisting of ICG.
The photoacoustic therapy was investigated for the ﬁrst
time in vitro and in vivo [24]. When photoacoustic
treatment was performed on mice, the laser and ICG-
PL-PEG-FA treatment caused signiﬁcant tumor sup-
pression.
In addition to PLAG, Wong and coworkers reported
the synthesis of ICG-containing nano/microcapsules
through a self-assembly chemistry [14]. Aqueous so-
lutions of polyallylamine hydrochloride (PAH) and di-
hydrogen phosphate salt are mixed together to form
spherical aggregates. ICG was encapsulated into the
NPs with electrostatic interactions. The reaction can
be carried out under mild conditions, such as room tem-
perature, aqueous solution, and neutral pH. The parti-
cle size range is 0.6-1.0 μm, and the maximum loading is
23 wt%. After that, Wong’s group further investigated
the ICG-nanocapsules, and developed three-step room-
temperature synthesis method for the preparation of
∼120 nm ICG-nanocapsules, and coated with antiepi-
dermal growth factor receptor(anti-EGFR) antibodies
for tumor cell targeting capability [25]. Photothermal
eﬀect of ICG-nanocapsules on EGFR-rich tumor cells
was investigated. Signiﬁcant thermal ablation of cancer
cells was observed for encapsulated ICG as compared
to free ICG at 808 nm laser irradiation with radiant
exposure of 6 W/cm2. This is the ﬁrst demonstration
of the theranostic ICG NPs for targeting ﬂuorescence
imaging and photothermal treatment of cancerous cells.
Recently, Yaseen et al. further investigated how the
surface coating and size of the ICG-nanocapsules inﬂu-
ences ICG’s biodistribution in vivo [26]. The results
indicated that the nanocapsules can enhance the deliv-
ery of ICG to organs other than the liver, particularly
the lung and spleen. Therefore, by manipulating syn-
thetic parameters, the uptake of ICG-nanocapsules, in
particular by the lung may potentially be controlled.
It oﬀers potential for the development of optically me-
diated diagnostic and treatment applications for these
organs.
ICG doped NPs
As inorganic material, SiO2 exhibits excellent sta-
bility and biocompatibility. The FDA listed silica as
“generally recognized as safe” [27]. ICG doped SiO2
NPs protect the ICG from photobleaching and pho-
todegradation. The silica surface also enables easy and
ﬂexible surface treatments. Recently, Quan et al. suc-
cessfully developed a method for preparation of ICG
doped silica NPs [28]. Cationic polymer polyethylen-
imine (PEI) was interacted with anion ICG, and the
ion-pair was encapsulated by a silica layer using the
sto¨ber method. The prepared ICG doped SiO2 NPs
have diameters in the range 50-200 nm. The isolation
of ICG molecules from the surroundings by the silica
layer greatly enhanced the photostability of ICG doped
SiO2 NPs. However, in vivo imaging and therapy abil-
ity of the ICG doped SiO2 NPs have not been inves-
tigated. Lee et al. reported ICG doped mesoporous
silica NPs for optical imaging in living mice for the
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ﬁrst time [29]. The high dispersion of ICG molecules
in the large surface areas of mesoporous silica could
eﬃciently prevent them from aggregation and thus de-
crease the ﬂuorescence self-quenching. In addition, the
nanochannels of mesoporous silica provided the con-
ﬁned space not only can protect ICG molecules from
the irreversible degradation but also diminish the im-
mune response. The studies of in vivo biodistribution of
ICG doped mesoporous silica revealed that the particles
in the size of 50-100 nm possessing relatively positive
surface charge were mainly targeting to the liver. In
addition to SiO2, ICG also can be doped into Ca3P2
NPs, a primary biomineral with good biocompatibil-
ity and biodegradation, using a double reverse micelle
technique [30]. After polyethylene glycol (PEG) sur-
face functionality, ICG-Ca3P2 NPs exhibit higher ﬂu-
orescent intensity, quantum eﬃciency and photostabil-
ity than the free ICG. The in vivo imaging indicated
that the ICG-Ca3P2 NPs can be accumulated in solid,
xenograft breast adenocarcinoma tumors via enhanced
retention and permeability (EPR) within 24 h after tail
vein injection in a nude mouse model.
ICG conjugated NPs
Chemical conjugate is an ideal way for the prepa-
ration of ICG NPs [31]. However, it is not easy to
introduce active groups on the ICG molecular due to
its symmetry of chemical structure. Therefore, this
strategy is not generally used. Recently, two deriva-
tives of ICG, ICG-Sulfo-OSu and azide-terminated
ICG, attracted much attentions. Mok et al. re-
ported the use of ICG-Sulfo-OSu for the preparation of
ICG-nanogel [32]. The carboxyl groups of hyaluronic
acid (HA) were activated via carbodiimide coupling
chemistry and reacted with ethylenediamine to pre-
pare amine modiﬁed hyaluronic acid (NH2-HA). Subse-
quently, the ICG-Sulfo-OSu was reacted with NH2-HA,
and formed ICG encapsulated HA. The ﬂuorescence of
ICG-nanogel is self-quenched due to its strong inter-
molecular hydrophobic interactions between ICGs. Un-
der the HAdase-overexpressing conditions, such as tu-
mor microenvironments and metastatic lymph nodes,
the ﬂuorescence of ICG-nanogel were recovered. As a
theranostic agent, the ICG-nanogel can be accumulated
speciﬁcally in tumor after intravenous injection, and en-
able visualization of tumors. Moreover, the ICG ﬂuo-
rescence can last three days after the injection. There-
fore, we could monitor biological responses and thera-
peutic eﬃcacy following treatment using ICG-nanogels.
In addition to using the EDC coupling reactions, click
chemistry, a highly eﬃcient conjugation reaction, is also
used for the synthesis of ICG conjugated NPs. Foulger
group reported the synthesis of azide-terminated ICG
by four steps of chemical reaction [33]. The ICG was
conjugated with poly(propargyl acrylate) (PA) NPs
with copper-catalyzed azide/alkyne cycloaddition. The
placement of ICG onto the surface of the particles al-
lows for the chromophore to complex with proteins that
resulted in the alteration and enhancement of the emis-
sion of the dye. Moreover, PDT studies indicated the
ICG-PA NPs with 780 nm radiation resulted in a sta-
tistically signiﬁcant reduction in cell growth. Based on
the results of these studies, Daniele et al. further de-
veloped protein-activated ICG-magnetic nanoclusters
[34]. The magnetic core could provide a MRI signal
and ICG-BSA shell show a highly ﬂuorescent imaging
ability. Therefore, this system presents the blueprint
for the next generation of multimodal imaging thera-
nostic platforms.
Conclusions
In the current article, we have highlighted some ICG
NPs that are currently under intensive investigation for
theranostic applications. These ICG NPs can not only
possess unique optical or photoacoustic imaging prop-
erties, but also can be used as therapeutic agents for
cancer therapy. The clinical demand of cancer imag-
ing and therapy has also led many researchers to turn
to this ﬁeld. However, despite the fast progress, there
have so far been few ICG NPs that are so developed
to meet clinical standards. Therefore, we still have a
long way to go in terms of using these nano-systems in
humans. The major questions include the following: 1)
the biocompatibility and biodegradable nature of nano-
carriers. 2) The low ﬂuorescence quantum yield. 3) The
low photothermal conversion eﬃciency. Furthermore,
highly speciﬁc targeting is the other important topic
that can never be over addressed. Therefore, much ef-
fort to address each of these issues is going on, and
should remain the focus in the future studies.
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